1-6 of 306 Activities
The treatment landscape for hemophilia A and B is expanding with strategies and therapies to optimize efficacy, provide durable hemostasis restoration, and improve safety. These contemporary approaches to care have also led to new pathways and assays for clinical and laboratory monitoring.
In this CME Outfitters Webcast, an interdisciplinary faculty, including a renowned patient advocate who has lived with hemophilia for many years, discuss the impact of key advances in treatment and monitoring on quality of care and outcomes. A focused segment on shared decision making (SDM) keeps the conversation grounded in counseling and collaboration and includes both clinician and patient perspectives.
In this CME Outfitters recorded webcast, leading clinical experts will help prepare learners to discuss, assess, and address bowel urgency in patients with UC, and will provide insight into the effects of new and emerging therapies.
In this CMEO Snack entitled, Early Detection, Better Direction: Tau Biomarkers and Amyloid-Targeting Therapies in Alzheimer’s Disease, expert faculty will discuss strategies for identifying the neuropathological chances associated with AD, assessing the role of phosphorylated tau biomarkers, evaluating latest data from clinical trials on ATTs, and identifying appropriate patients to ensure timely and optimal management.
Henrik Zetterberg, MD, PhD, is Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London (UCL), UK, and a clinical chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, leads the UK DRI Fluid Biomarker Laboratory at UCL, and is a key member of the Hong Kong Center for Neurodegenerative Diseases and Visiting Professor in the University of Wisconsin (UW) Department of Medicine, School of Medicine and Public Health, Madison, Wisconsin. His main research focus and clinical interest are in fluid biomarkers for brain diseases, neurodegenerative diseases in particular. He has published more than 2,000 scientific articles and received many awards.
Data from recent clinical trials for first-line combination options using immunotherapies for ovarian cancer (OC) can be challenging for clinicians with no experience selecting patients for combinatorial treatment approaches or using combination therapies for their patients. During this podcast, Drs. Richard Penson and Ramez Eskander will educate clinicians on the use of immune checkpoint inhibitors for the treatment of OC and the use of biomarker analyses to optimize patient selection.
Richard T. Penson, MD, MRCP, is a Medical Oncologist at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School. A key opinion leader, Dr. Penson was a longstanding member of the Gynecologic Oncology Group Ovarian and Quality of Life Committees and now serves on the Foundation’s Investigator Council. He is the national Principal Investigator (PI) of the olaparib registration trial (SOLO-2) and the international PI of SOLO3, and the OVAL trial. He has taught on Harvard’s Practice of Medicine Course, the Bigelow General Medical Service at Massachusetts General Hospital, and is one of the Chairs of the Institutional Review Board of Dana-Farber Harvard Cancer Center.
The CME Outfitters Diversity, Equity, and Inclusion (DE&I) phase 1 initiative focused on six key therapeutic areas: maternal health, cardiovascular care, pain management, oral health, dermatologic health/melanoma, and elective surgery. Each of these areas face significant health inequities, leading to increased morbidity and mortality rates among underserved populations. This digital monograph illustrates the impact of the educational initiative on HCP knowledge and competence as well as patient outcomes.
Monica Peek, MD, MPH, MSc is an Ellen H. Block Professor of Health Justice in the Department of Medicine. She is also the Associate Director, Chicago Center for Diabetes Translation Research, and Director of Research, MacLean Center for Clinical Medical Ethics. She is a practicing internist, medical educator, and clinician investigator. Her research pursues health equity and social justice, with a focus on promoting equitable doctor/patient relationships among racial minorities, integrating the medical and social needs of patients, and addressing health care discrimination and structural racism impacting health outcomes (e.g., diabetes, COVID-19). Dr. Peek has authored more than 200 peer-reviewed publications and abstracts on health care disparities, diversity, and bias; has been the principal investigator of multiple grants to address health disparities; and has been invited to speak at numerous local and national medical meetings.
In the third activity of this CME Outfitters BriefCase series, expert faculty utilize case-based learning to instruct learners on incorporating efficacy and safety data for biologics indicated for PsO and PsA in patients as part of treatment decision-making.
Melodie Young has more than 30 years in dermatology as a nurse practitioner and has focused her career on immune-mediated skin disease. She has been the Principal Investigator or Sub-Investigator in more than 80 clinical trials and has more than 40 scholarly publications. She is the former Director of the Baylor Psoriasis Center, National Psoriasis Tissue Bank, and a former member of the Medical Advisory Board of the National Psoriasis Foundation. Young is a founding member of the International Psoriasis Council.